Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects

Neuregulin‑1, a microvascular endothelial‑derived protein, protects against myocardial ischemia‑reperfusion injury (Review)

(2020) Yuhao Lin et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease

(2020) Andrew Geissler et al.   CLINICAL SCIENCE

Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarction

(2017) Tom J. Parry et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effects of neuregulin-1 on autonomic nervous system remodeling post-myocardial infarction in a rat model

(2017) Xi Wang et al.   Neural Regeneration Research

Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa)

(2017) Merrie Mosedale et al.   TOXICOLOGICAL SCIENCES

Calcium cycling proteins and heart failure: mechanisms and therapeutics

(2013) Andrew R. Marks   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats

(2011) Bingong Li et al.   Cardiovascular Diabetology

Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses

(2010) Andrew Jabbour et al.   EUROPEAN JOURNAL OF HEART FAILURE

A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart Failure

(2010) Runlin Gao et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure

(2008) Yasuhiro Ikeda et al.   PHYSIOLOGY